Business Wire

Yard Force Robotic Mowers Have Obtained "Green Product" Mark by TÜV

Share

Yard Force, a leading manufacturer of innovative outdoor power equipment, has announced the launch of its MB400 and MB800 robotic mowers on the German market. These models come equipped with Bluetooth and app control, providing users with convenient and easy access to their mowers from their smartphones or tablets.

In addition to their advanced technology features, both the Yard Force MB400 and MB800 come with a unique feature that allows for decking to be cleaned using water. This innovative feature not only makes cleaning the decking easier, but also helps to prevent the build-up of algae and other contaminants that can affect the appearance and longevity of the decking.

The Yard Force MB400 and MB800 are also equipped with a free garage, providing users with a convenient and secure storage solution for their mowers. This is particularly useful for those who wish the robotic mower could find shelter during rain or snow and use the robotic mower for a longer life.

Yard Force launches the two new models on the 10th anniversary of its robotic mowers, setting the standard once again:
In addition to their impressive features, both the Yard Force MB400 and MB800 have been awarded the "Green Product" certification by TÜV, a leading certification organizaition for environmental, social, and governance (ESG) standards. This certification recognizes the mowers' eco-friendly design and technology, making them a smart and sustainable choice for homeowners looking to reduce their carbon footprint.

In 2013, the company started selling its robotic mowers in Germany and has since equipped tens of thousands of German gardens with the innovative and practical robotic mowers.

The new Yard Force MB400 and MB800 are designed to provide users with a convenient and efficient solution for maintaining their lawns. With maximum 400m2 and 800 m2 working area respectively, these mowers are perfect for small to medium sized lawns, and can easily navigate around obstacles such as trees and garden furniture.

The Bluetooth and app control features of the Yard Force MB400 and MB800 allow users to easily set up and customize their mowing schedule, as well as monitor the mower's performance and receive notifications on their smartphone or tablet. This level of control and convenience makes the MB400 and MB800 a popular choice for busy homeowners who want to maintain their lawns without the hassle of traditional mowing methods.

The decking cleaning feature of the Yard Force MB400 and MB800 is another standout feature that sets these mowers apart from their competitors. By using water to clean the decking, users can easily remove dirt and debris, ensuring that their decking stays looking clean and fresh all year round. This feature also helps to prevent the build-up of algae and other contaminants, which can damage the decking and reduce its lifespan.

Overall, the Yard Force MB400 and MB800 are a highly innovative and convenient solution for maintaining a healthy and well-groomed lawn. With their advanced technology, eco-friendly design, and unique decking cleaning feature, these mowers are sure to be a hit with German homeowners looking for a more efficient and sustainable way to care for their lawns.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Email: linyinlu@sumec.com.cn
Phone number: +86-13770517766

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye